Positive proof of concept experiences can lead to the first treatment in the world for celiac disease

Student treatment of celiac disease effectively controls the disease – at least in an animal model – in a first therapy of its kind for a disease that affects around 70 million people worldwide.

Currently, there is no treatment for celiac disease, which is caused by gluten food exposure, a protein in wheat, barley and rye. Grains can produce serious intestinal symptoms, resulting in inflammation and bloating.

Indeed, celiac disease is the scourge of lovers of bread and pasta around the world, and despite the maintenance of a gluten-free diet without gluten-free, the disease can still lead to social isolation and poor nutrition, according to gastroenterologists. It is a serious autoimmune disorder which, when left untreated, can cause malnutrition, bone loss, anemia and high risk of cancer, mainly intestinal lymphoma.

Now, an international team of scientists led by researchers in Switzerland hope to change the fate of the Coeliacs for the best. A series of innovative experiences has produced a technique of “cell sphotation” which targets regulatory T cells, the components of the immune system commonly called t_rules.

The technique based on cells borrows from a form of therapy against cancer and underpins a unique discovery which could possibly lead to a new processing strategy, suggest the data of the study.

“Coeliac disease is a chronic inflammatory inflammatory disorder of the small intestine with a global prevalence of around 1%,” writes Dr. Raphaël Porret, principal author of research published in Translational scientific medicine.

“The condition is caused by an immune response unsuitable for gluten cereal proteins, which causes tissue damage to the intestine and the training of autoantibodies towards the transglutaminase enzyme,” continued Porret, researcher from the Department of Immunology and Allergy at the University of Lausanne.

Working with colleagues from the University of California in San Francisco, as well as the Norwegian Caliac Disease Research Center at the University of Oslo, Porret and his colleagues have advanced a new concept. They theorize that a form of cell therapy, based on a revolutionary form of cancer treatment, could also work against celiac disease.

In an animal model, Porret and his world team of researchers have tested the equivalent of car cell therapy against celiac disease. The team recognized that the “t_register The contribution to the natural history of celiac disease is always controversial, “but researchers have also shown that at least in their animal model of human celiac disease, the treatment worked.

TT T cell therapy is a type of cancer immunotherapy in which a patient T cells are genetically modified in the laboratory to recognize and kill cancer cells. The cells are then infused in the patient to provide a form of cancer treatment 24 hours a day. In the case of celiac disease, T cells are modified to affect the activity of T cells which become hyperactive in the presence of gluten.

To do this work, the researchers had to know all the aspects of the immune response against gluten. “Coeliac disease, gluten-sensitive enteropathy, demonstrates a strong combination of human leukocyte antigen, with more than 90% of patients bearing the HLA-DQ2.5 Allotype,” wrote Porret, describing the antigen profile of human leukocytes of most patients with celiac disease.

As a new treatment against the condition, the team has designed the regulatory effectors and T effects and has successfully tested them in their animal model. Scientists have perfected these cells in mouse and evaluated the capacity of regulatory T cells to calm the response of T effects with gluten. They observed that oral exposure to gluten had caused a display to the workforce cells when they were infused without the modified t_rules.

However, engineering regulatory T cells have prevented this intestinal migration and abolished the proliferation of effector T cells in response to gluten. Although it is a first step, the first promising results indicate that cell therapy approaches could one day lead to treatment for a long time sought for this debilitating intestinal disorder.

“Our study opens the way to a better understanding of the main stages activating the antigen after the absorption of food antigen (gluten)”, concluded porret. “Although additional work is necessary to assess t_register Efficiency within the framework of an active disease, our study provides evidence of proof of concept which have designed_rules Hold the therapeutic potential to restore gluten tolerance in patients with celiac disease. “”

© 2025 Science X Network